This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics


  • 00
  • 00
  • 00
  • 00
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Ved Srivastava, PhD
CTO at Perpetual Medicines


Dr. Ved Srivastava is currently CTO of Perpetual Medicines. Prior to that, he was Vice President of Peptide Chemistry at Atkis Oncology and the Head of Peptide Chemistry at Intarcia Therapeutics and GlaxoSmithKline, USA; and in the leadership role at Amylin Pharmaceuticals (Astra Zeneca), USA. Ved is President-Elect of the American Peptide Society.

Ved has significantly participated in the development and commercialization of SymlinTM, ByettaTM, and BydeureonTM, first-in-class medicines for the treatment of diabetes. Ved has over 25 years of experience with expertise in drug discovery and development in metabolic diseases, CNS, and inflammation with major emphasis in peptide medicinal chemistry, peptide drug delivery and chemistry manufacturing and control (CMC). Ved is the Editor of four books (1) Peptide-based Drug Discovery - Challenges and New Therapeutics, (2) Comprehensive Medicinal Chemistry IIIrd edition, Volume 6. Biologics Medicine (3) ‘Peptide 2015’ and (4) Peptide Therapeutics: Strategy and Tactics for Chemistry Manufacturing and Control (in print). Ved earned a Ph.D. in organic chemistry from the University of Lucknow, India.

Ved Srivastava, PhD's Network

Agenda Sessions

  • Chairman’s Remarks: Targeted Radiopharmaceuticals: Progress to the Clinic